To test this hypothesis, we initially studied MOLT-3 cells, an immortalized T-ALL cell line with wildtype TP53, and generated isogenic cell lines edited at TP53 or the AAVS1 safe-harbor locus (control). The gene discussed is TP53; the disease is acute lymphoblastic leukemia.